

The Bidirectional Relationship Between Anxiety Disorders and Benzodiazepine Addiction in Gen-Z

M Nirmala Priyadarshanie*

Department of Nursing & Midwifery, Faculty of Allied Health Sciences, General Sir John Kotelawala Defence University, Sri Lanka

Keywords: Anxiety Disorders; Benzodiazepine Addiction; Gen-Z; Bidirectional Relationship; Mental Health; Substance Dependence; Prescription Drugs; Youth Mental Health; Sedative Abuse; Comorbidity; Psychiatric Disorders; Benzodiazepines; Young Adults; Coping Mechanisms.

Introduction

The rising prevalence of anxiety disorders among Generation Z (Gen-Z) has sparked concern among mental health professionals, educators, and policymakers. Coinciding with this trend is an increase in the misuse and dependency on benzodiazepines—a class of sedatives commonly prescribed for anxiety. While benzodiazepines can be effective in managing acute symptoms of anxiety, their long-term use carries a high risk of addiction, particularly in young populations. This paper explores the bidirectional relationship between anxiety disorders and benzodiazepine addiction within Gen-Z, examining how these conditions influence each other and contribute to a worsening mental health crisis among young adults [1-4].

Description

Generation Z, comprising individuals born roughly between 1997 and 2012, faces unique challenges that have contributed to an uptick in anxiety-related mental health issues. Factors such as academic pressure, job insecurity, climate anxiety, social media comparison, and a constant digital presence contribute to elevated stress levels. In response to these pressures, many Gen-Z individuals are being prescribed benzodiazepines like Xanax, Ativan, or Klonopin to manage symptoms of anxiety, panic attacks, or insomnia [5-9].

Benzodiazepines function by enhancing the effect of GABA (gamma-aminobutyric acid), a neurotransmitter that promotes calm and relaxation. While effective for short-term use, these drugs are associated with a high potential for dependency. The sedative and calming effects can lead to repeated use as a coping mechanism, even in the absence of medical guidance. Alarming, misuse among Gen-Z is often linked not only to medical prescriptions but also to recreational use and self-medication—especially when mental health support is inadequate or inaccessible [10].

Discussion

The relationship between anxiety disorders and benzodiazepine addiction is inherently bidirectional. For many in Gen-Z, anxiety disorders precede benzodiazepine use. They may initially be prescribed these medications to cope with severe symptoms. However, over time, dependence can develop, leading to higher dosages, withdrawal symptoms, and a cycle of addiction. As dependence on the drug deepens, anxiety may paradoxically worsen, particularly during withdrawal periods, reinforcing the need for continued use.

Conversely, some individuals may begin misusing benzodiazepines recreationally or as a form of emotional self-medication. This misuse can lead to the development or intensification of anxiety symptoms, especially once the brain adapts to the presence of the drug. Once the

body develops a tolerance, higher doses are needed to achieve the same calming effect, which exacerbates both dependency and underlying anxiety.

Social media, online peer pressure, and glamorization of “chill pills” and sedatives play a significant role in normalizing benzodiazepine misuse among Gen-Z. These cultural factors, combined with the relative ease of acquiring prescriptions or illicit pills, create a perfect storm for addiction to develop.

Furthermore, Gen-Z often lacks adequate access to long-term mental health care. Many young people face barriers such as cost, stigma, or unavailability of qualified professionals, leading them to rely more heavily on quick pharmacological solutions rather than therapy or behavioral interventions. This reliance fosters a cycle in which anxiety is treated symptomatically but not at its root.

Understanding the bidirectional relationship is critical for intervention. Clinicians must approach treatment holistically—screening for substance misuse when diagnosing anxiety, and vice versa. Early education about the risks of benzodiazepines, paired with access to safer alternatives such as cognitive behavioral therapy (CBT), mindfulness practices, and peer support, can help disrupt the cycle.

Conclusion

The interplay between anxiety disorders and benzodiazepine addiction in Gen-Z is a growing public health concern. This bidirectional relationship is marked by a dangerous feedback loop: anxiety leads to benzodiazepine use, which can then foster dependence and further anxiety. As Gen-Z navigates unprecedented social and psychological pressures, it is imperative to address the root causes of anxiety while promoting safe and sustainable treatment options. Healthcare providers, educators, and policymakers must collaborate to improve access to mental health care, regulate prescription practices, and educate youth on the risks associated with benzodiazepine use. Breaking the cycle requires both preventive strategies and compassionate, individualized care. Recognizing the deep interconnection between mental health and substance use is the first step in building a healthier future for this generation.

***Corresponding author:** M Nirmala Priyadarshanie, Department of Nursing & Midwifery, Faculty of Allied Health Sciences, General Sir John Kotelawala Defence University, Sri Lanka, E-mail: nirmalapriyadarshanie90@gmail.com

Received: 03-Feb-2024, Manuscript No: jart-25-164336, **Editor Assigned:** 06- Feb-2024, Pre QC No: jart-25-164336 (PQ), **Reviewed:** 14- Feb-2024, QC No: jart-25-164336, **Revised:** 24-Feb-2024, Manuscript No: jart-25-164336 (R), **Published:** 28-Feb-2024, DOI: 10.4172/2155-6105.100746

Citation: Priyadarshanie MN (2025) The Bidirectional Relationship Between Anxiety Disorders and Benzodiazepine Addiction in Gen-Z. J Addict Res Ther 16: 746.

Copyright: © 2025 Priyadarshanie MN. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

1. Pascarosia P, Futterman S (1976) Ethnopsychedelical therapy for alcoholics: observations in the peyote ritual of the native American church. *J Psychedelic Drugs* 8: 215-21.
2. Blum K, Futterman SL, Pascarosia P (1977) Peyote, a potential ethnopharmacologic agent for alcoholism and other drug dependencies: possible biochemical rationale. *Clin Toxicol* 11: 459-72.
3. Agin-Liebes G, Haas TF, Lancelotta R, Uthaug MV, Ramaekers JG, et al. (2021) Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. *ACS Pharmacol Trans Sci* 4: 543-52.
4. Mash DC, Kovera CA, Pablo J, Tyndale R, Ervin FR, et al. (2001) Ibogaine in the treatment of heroin withdrawal. *Alkaloids Chem Biol* 56: 155-71.
5. Noller GE, Frampton CM, Yazar-Klosinski B (2018) Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. *Am J Drug Alcohol Abuse* 44: 37-46.
6. Brown TK (2013) Ibogaine in the treatment of substance dependence. *Curr Drug Abuse Rev* 6: 3-16.
7. Malcolm BJ, Polanco M, Barsuglia JP (2018) Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing Ibogaine. *J Psychoactive Drugs* 50: 256-65.
8. Mash DC, Duque L, Page B, Allen-Ferdinand K (2018) Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes. *Front Pharmacol* 9: 529.
9. Barsuglia JP, Polanco M, Palmer R, Malcolm BJ, Kelmendi B, et al. (2018) A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder. *Prog. Brain Res* 242: 121-58.
10. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, et al. (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. *J Psychopharmacol* 29: 289-99.